Investing in the science that defines tomorrow’s medicine

Explore Portfolio Meet our Team

Luma Group funds early and mid-stage biotechnology companies. Our approach integrates AI-driven analysis, scientific rigor, and an advisor network spanning research, clinical practice, and industry leadership.

Explore Portfolio

Scientific rigor enhanced by AI

We pair deep scientific discipline with advanced AI to evaluate opportunities with clarity and precision.

Accelerated insight with LABI

Our AI system speeds up how we analyze data, validate breakthroughs, and uncover real potential.

Hands-on industry leadership

We work closely with founders through research, development, and scale to turn science into lasting impact.

Breakthrough science. Disciplined execution.

We back early and mid-stage biotech teams advancing therapeutics, platform technologies, and biological computation—supporting solutions that can meaningfully scale human health.

Explore Portfolio

Research, analysis, and updates from our network

Articles, whitepapers, and expert commentary.

See More Insights

February 1, 2025

Decoding Aging: Breakthroughs, Challenges and the Future of Longevity Drug Development

For centuries, humans have sought to understand—and potentially slow, halt or reverse—the aging process. Recent advances in molecular and cellular biology have begun to illuminate the core hallmarks and drivers of aging, providing a foundational framework for new therapeutic approaches. While some of these therapies have not fulfilled their initial promise, others have achieved remarkable progress, and ongoing clinical trials may pave the way for a new class of longevity drugs. Still, despite growing optimism, the journey toward regulatory approval and widespread adoption of these treatments presents a unique set of challenges that must be navigated carefully.

The New Era of Multi-OMICs Therapy: Our investment in Character Bio

Age-related macular degeneration (AMD) affects millions worldwide, leading to progressive vision loss and limited treatment options. Character Bio is changing that paradigm by combining an AI-driven multi-omics platform with the world’s richest AMD dataset to develop new precision therapies for these patients. At Luma, we invest in transformative companies, and Character Bio’s groundbreaking work promises to redefine the future of eye health.

The Case for Venture Capital in Biotechnology

There are many perceptions of what a venture capitalist (VC) is. In the biotech space, VCs are enigmatic because many of us never imagined becoming VCs, and many future VCs might have no idea they’re headed down that path either. My story, like many in biotech, started with a passion to help sick people. I was fortunate to discover my passion at the age of six, when I told my parents that I wanted to be a genetic engineer. I didn’t fully understand what that entailed, but the film Jurassic Park sparked my curiosity. I was fascinated by the idea that nature had invented biological Legos called DNA that could be assembled to create humans, sea slugs, bananas, bacteria, mold, and, most intriguingly, entirely new life forms. Less than two decades later, I received my PhD in Molecular and Cellular Biology. I loved deciphering nature’s clues and genetic codes to figure out the “how” and “why” in nature’s playbook. However, I didn’t yet know how to translate this knowledge from the lab into life-saving therapies. I continued my research journey post-PhD and eventually landed an industry postdoc position at Pfizer. At Pfizer, I soaked up every fact, lesson, piece of jargon, and process required to take an initial discovery and turn it into a drug. At this moment, something clicked for me: my true passion wasn’t just making discoveries; it was figuring out how to transform those discoveries into medicines capable of helping patients. My time at Pfizer also made it clear that I wasn’t ready to join an organization as large as Pfizer long-term. Thankfully, after years of trying different career trajectories and with the help of some great mentors, it became clear that biotech venture capital uniquely aligned both my personal goals: contributing to life-changing therapies, and professional goals: being able to earn a living while pursuing my personal passion. As they say, “Do what you love, and you’ll never work a day in your life.”